Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Breast 1

Conditions

Breast Neoplasms 9Endometrial Neoplasms 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Breast Diseases 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Fulvestrant 4ribociclib 3palbociclib 3abemaciclib 3Anastrozole 3selpercatinib 2exemestane 2Trastuzumab 2Letrozole 2Gonadotropin-Releasing Hormone 2Docetaxel 2AZD9833 2tucatinib 1ipatasertib 1glutathione pegylated liposomal doxorubicin 1entinostat 1elacestrant 1atezolizumab 1alectinib 1Zoledronic Acid 1Watchful Waiting 1Trabectedin 1Tamoxifen 1Sodium Chloride 1STX-478 1RAD1901 1Paclitaxel 1Metformin 1Imlunestrant 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms by Site × Imlunestrant × Breast × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡